File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Targeting Mitosis in Cancer: Emerging Strategies

TitleTargeting Mitosis in Cancer: Emerging Strategies
Authors
Issue Date2015
Citation
Molecular Cell, 2015, v. 60, n. 4, p. 524-536 How to Cite?
Abstract© 2015 Elsevier Inc. The cell cycle is an evolutionarily conserved process necessary for mammalian cell growth and development. Because cell-cycle aberrations are a hallmark of cancer, this process has been the target of anti-cancer therapeutics for decades. However, despite numerous clinical trials, cell-cycle-targeting agents have generally failed in the clinic. This review briefly examines past cell-cycle-targeted therapeutics and outlines how experience with these agents has provided valuable insight to refine and improve anti-mitotic strategies. An overview of emerging anti-mitotic approaches with promising pre-clinical results is provided, and the concept of exploiting the genomic instability of tumor cells through therapeutic inhibition of mitotic checkpoints is discussed. We believe this strategy has a high likelihood of success given its potential to enhance therapeutic index by targeting tumor-specific vulnerabilities. This reasoning stimulated our development of novel inhibitors targeting the critical regulators of genomic stability and the mitotic checkpoint: AURKA, PLK4, and Mps1/TTK.
Persistent Identifierhttp://hdl.handle.net/10722/292915
ISSN
2023 Impact Factor: 14.5
2023 SCImago Journal Rankings: 9.332
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorDominguez-Brauer, Carmen-
dc.contributor.authorThu, Kelsie L.-
dc.contributor.authorMason, Jacqueline M.-
dc.contributor.authorBlaser, Heiko-
dc.contributor.authorBray, Mark R.-
dc.contributor.authorMak, Tak W.-
dc.date.accessioned2020-11-17T14:57:29Z-
dc.date.available2020-11-17T14:57:29Z-
dc.date.issued2015-
dc.identifier.citationMolecular Cell, 2015, v. 60, n. 4, p. 524-536-
dc.identifier.issn1097-2765-
dc.identifier.urihttp://hdl.handle.net/10722/292915-
dc.description.abstract© 2015 Elsevier Inc. The cell cycle is an evolutionarily conserved process necessary for mammalian cell growth and development. Because cell-cycle aberrations are a hallmark of cancer, this process has been the target of anti-cancer therapeutics for decades. However, despite numerous clinical trials, cell-cycle-targeting agents have generally failed in the clinic. This review briefly examines past cell-cycle-targeted therapeutics and outlines how experience with these agents has provided valuable insight to refine and improve anti-mitotic strategies. An overview of emerging anti-mitotic approaches with promising pre-clinical results is provided, and the concept of exploiting the genomic instability of tumor cells through therapeutic inhibition of mitotic checkpoints is discussed. We believe this strategy has a high likelihood of success given its potential to enhance therapeutic index by targeting tumor-specific vulnerabilities. This reasoning stimulated our development of novel inhibitors targeting the critical regulators of genomic stability and the mitotic checkpoint: AURKA, PLK4, and Mps1/TTK.-
dc.languageeng-
dc.relation.ispartofMolecular Cell-
dc.titleTargeting Mitosis in Cancer: Emerging Strategies-
dc.typeArticle-
dc.description.naturelink_to_OA_fulltext-
dc.identifier.doi10.1016/j.molcel.2015.11.006-
dc.identifier.pmid26590712-
dc.identifier.scopuseid_2-s2.0-84947753819-
dc.identifier.volume60-
dc.identifier.issue4-
dc.identifier.spage524-
dc.identifier.epage536-
dc.identifier.eissn1097-4164-
dc.identifier.isiWOS:000368288700004-
dc.identifier.issnl1097-2765-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats